Galera Schedules Type A Meeting With FDA To Discuss Next Steps For Its Radiotherapy Avasopasem
Portfolio Pulse from Benzinga Newsdesk
Galera Therapeutics has scheduled a Type A meeting with the FDA to discuss the next steps for its radiotherapy Avasopasem. The company is seeking guidance on the regulatory path forward for the drug.
September 18, 2023 | 11:22 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Galera Therapeutics' upcoming meeting with the FDA regarding its radiotherapy Avasopasem could potentially impact the company's stock. The outcome of the meeting could either boost or hinder the company's progress.
The meeting with the FDA is crucial for Galera Therapeutics as it will determine the future of Avasopasem. Positive feedback from the FDA could boost the company's stock as it would mean progress in the drug's development. Conversely, negative feedback could hinder the company's progress and potentially negatively impact the stock.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100